Wave Life Sci Ord Sh (WVE) Stock Price, Quote & News

Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of...

Industry: Biotechnology

Sector: Healthcare

Phone: 65 6236 3388

Website: wavelifesciences.com

Address:

Marina One East Tower, 7 Straits View No.12-00, Singapore, Singapore

aga5757st Mar. 12 at 1:15 AM

$WVE Simply curious, does anyone know what Biopharmapro (Terry Chrisomalis. on SA) opinion, if any on WVE and ARWR? He last gave GPCR a strong buy rec.

0 · Reply

aga5757st Mar. 11 at 8:23 PM

$WVE And personally, I have seen the FDA; DDMAC (in "olden" days) and OPDP, 'today' take particular, inconsistent or less than straight forward paths with biotech dev. companies. So, glad the message is clear: The FDA better evolve to protect the public, etc.; yet, fully realize the massive global risk for not being, fully, scientifically calibrated in approval process of paradigm shifting medical advance. It would be unacceptable, unsupportable and a disaster in various forms to the U.S.A. if they don't immediately, rapidly, yet prudently evolve. Thanks to B_B and a few others that highlighted changes from leadership (V. Prasad's exit) to restarts or reviews in the biologics/genetic platforms.

0 · Reply

aga5757st Mar. 11 at 8:13 PM

$WVE I'm a busy unshy guy......B_B is great. He's got his perspective and shares. People, human BEINGS or whatever Carbon based live that's alive & well just needs to participate. Simple.

0 · Reply

B_B_ Mar. 11 at 8:03 PM

$WVE You can BLOCK me. The button is on the right.

1 · Reply

aletz Mar. 11 at 7:45 PM

$WVE is this place @B_B_ 's personal blog?

0 · Reply

B_B_ Mar. 11 at 3:36 PM

$WVE If Paul announces the news this week, it’ll probably be new data or deals, but if it’s next week, it could be a buyout, I think.

0 · Reply

aga5757st Mar. 11 at 3:02 PM

$WVE So with a current Mkt CAP 2.67B. What do we see, a buy out at what premium to match or exceed greatly the following: Company WAVE LIFE SCIENCES LTD Buy Out Price GPCR - 4.16B $29.71 VKTX - 4.05B $28.93 ARWR - 8.29B $59.21 Projected Market CAP/Outstanding Shares (WVE 140.03M) Just messin' around, not dreaming, not anticipating, just conservative estimates on current prices to companies in obesity development comp. I like ARWR with what they are doing in a variety of therapeutic areas beyond obesity I know far more about (e.g. cardiovascular, pulmonary, MASH).

0 · Reply

B_B_ Mar. 11 at 2:54 PM

$WVE

0 · Reply

B_B_ Mar. 11 at 2:28 PM

$WVE I can see it in the stars. It’s only a matter of days, not weeks, before Paul drops the news.

1 · Reply

B_B_ Mar. 11 at 1:54 PM

$WVE Paul, hurry up! Lilly to Invest $3 Billion in China to Boost Obesity Pill By Amber Tong March 11, 2026 Eli Lilly & Co will invest $3 billion in China over the next decade to expand local production, with a focus on weight loss as the US drugmaker looks to cement its dominance in the booming obesity market. https://www.bloomberg.com/news/articles/2026-03-11/lilly-to-invest-3-billion-in-china-to-boost-obesity-pill Ascletis eyes quarterly GLP-1 dosing following phase 2 obesity readout By Nick Paul Taylor Mar 10, 2026 https://www.fiercebiotech.com/biotech/ascletis-posts-phase-2-obesity-data-touts-potential-quarterly-glp-1-dosing

0 · Reply

FDA reversals leave investors worrying about the fates of other experimental drugs

DNLI MRNA RGNX

Mar 5, 2026, 8:30 AM EST - 6 days ago

Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference

Feb 26, 2026, 3:57 PM EST - 13 days ago

Wave Life Sciences Ltd. (WVE) Q4 2025 Earnings Call Transcript

Feb 26, 2026, 7:30 AM EST - 13 days ago

Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 23, 2026, 8:30 AM EST - 16 days ago

Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 19, 2026, 8:30 AM EST - 20 days ago

Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026

Feb 2, 2026, 2:16 PM EST - 5 weeks ago

Wave Life Sciences Reclaims Rare Disease Drug From GSK, Targets Faster FDA Path

GSK

Feb 2, 2026, 7:30 AM EST - 5 weeks ago

Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency

Jan 21, 2026, 12:40 PM EST - 7 weeks ago

MoneyShow's Best Investment Ideas For 2026: Part 9

GWW TGT TTD UFPT USAC VZ WLDN

Jan 13, 2026, 8:26 PM EST - 2 months ago

Wave Life Sciences Ltd. (WVE) Presents at 44th Annual J.P.

Jan 12, 2026, 7:30 AM EST - 2 months ago

Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio

Jan 5, 2026, 8:30 AM EST - 2 months ago

Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 15, 2025, 6:30 AM EST - 3 months ago

Why Did Wave Life Sciences Surge 147%?

Dec 9, 2025, 9:50 PM EST - 3 months ago

Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Dec 9, 2025, 2:11 PM EST - 3 months ago

What's Going On With Wave Life Sciences Stock Tuesday?

Dec 8, 2025, 4:01 PM EST - 3 months ago

Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Dec 8, 2025, 3:17 PM EST - 3 months ago

Wave Life Sciences Ltd. (WVE) Discusses Positive Interim Data from INLIGHT Trial of WVE-007 for Obesity Transcript

Dec 8, 2025, 7:30 AM EST - 3 months ago

Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss

Dec 7, 2025, 4:00 PM EST - 3 months ago

Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025

Dec 5, 2025, 4:12 PM EST - 3 months ago

Wave Life Sciences: Being Realistic, There Is Still So Much To Prove

Nov 11, 2025, 11:46 AM EST - 4 months ago

These Analysts Revise Their Forecasts On Wave Life Sciences Following Q3 Results

Nov 10, 2025, 8:01 PM EST - 4 months ago

Wave Life Sciences Ltd. (WVE) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 7:30 AM EST - 4 months ago

Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 7, 2025, 8:30 AM EST - 4 months ago

Wave Life Sciences to Present at Upcoming Investor Conferences

Nov 4, 2025, 8:30 PM EST - 4 months ago

Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025

Nov 4, 2025, 8:30 AM EST - 4 months ago

Wave Life Sciences Third Quarter 2025 Financial Results Scheduled for November 10, 2025

Nov 1, 2025, 3:06 AM EDT - 4 months ago

Wave Life Sciences Ltd. (WVE) Spotlight on RNA Editing and RNAi: Pipeline and Clinical Advances in Oligonucleotide Therapeutics Transcript

Oct 29, 2025, 10:50 PM EDT - 4 months ago

Correcting and Replacing Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day

Oct 29, 2025, 4:15 PM EDT - 4 months ago

Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day

Sep 18, 2025, 8:30 AM EDT - 6 months ago

Wave Life Sciences Announces Virtual Research Day on October 29th and Participation at Upcoming Investor Conferences

Sep 3, 2025, 3:10 PM EDT - 6 months ago

Wave Life Sciences Ltd. (WVE) Positive RestorAATion-2 Clinical Data Update Conference Transcript

Sep 3, 2025, 1:28 PM EDT - 6 months ago

Why Is GSK Partner Wave Life Sciences Stock Trading Lower On Wednesday?

GSK

Sep 3, 2025, 7:30 AM EDT - 6 months ago

Wave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency

Jul 30, 2025, 9:38 PM EDT - 8 months ago

Wave Life Sciences Ltd. (WVE) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 7:30 AM EDT - 8 months ago

Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 23, 2025, 8:30 AM EDT - 8 months ago

Wave Life Sciences Second Quarter 2025 Financial Results Scheduled for July 30, 2025

Jul 7, 2025, 5:42 PM EDT - 8 months ago

Wave Life Sciences: Upgrading Rating To Buy After Turbulent 10 Months

Jun 20, 2025, 4:01 PM EDT - 9 months ago

Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007's Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions

May 29, 2025, 8:30 AM EDT - 10 months ago

Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference

May 28, 2025, 8:00 AM EDT - 10 months ago

Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer

May 9, 2025, 4:57 PM EDT - 10 months ago

Wave Life Sciences Ltd. (WVE) Q1 2025 Earnings Call Transcript

May 8, 2025, 7:30 AM EDT - 10 months ago

Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 8:30 AM EDT - 11 months ago

Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025

Mar 27, 2025, 3:54 PM EDT - 1 year ago

Wave Life Sciences: Potential For Accelerated Approval Pathway With WVE-N531

Mar 26, 2025, 10:21 AM EDT - 1 year ago

Wave Life Sciences Stock Jumps On Positive Data From Muscle Disorder Drug, Plans FDA Submission Next Year

Mar 26, 2025, 7:30 AM EDT - 1 year ago

Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531

Mar 4, 2025, 3:16 PM EST - 1 year ago

Wave Life Sciences Ltd. (WVE) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 7:30 AM EST - 1 year ago

Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 25, 2025, 8:30 AM EST - 1 year ago

Wave Life Sciences Fourth Quarter and Full Year 2024 Financial Results Scheduled for March 4, 2025

Feb 6, 2025, 8:30 AM EST - 1 year ago

Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity

aga5757st Mar. 12 at 1:15 AM

$WVE Simply curious, does anyone know what Biopharmapro (Terry Chrisomalis. on SA) opinion, if any on WVE and ARWR? He last gave GPCR a strong buy rec.

0 · Reply

aga5757st Mar. 11 at 8:23 PM

0 · Reply

aga5757st Mar. 11 at 8:13 PM

$WVE I'm a busy unshy guy......B_B is great. He's got his perspective and shares. People, human BEINGS or whatever Carbon based live that's alive & well just needs to participate. Simple.

0 · Reply

B_B_ Mar. 11 at 8:03 PM

$WVE You can BLOCK me. The button is on the right.

1 · Reply

aletz Mar. 11 at 7:45 PM

$WVE is this place @B_B_ 's personal blog?

0 · Reply

B_B_ Mar. 11 at 3:36 PM

$WVE If Paul announces the news this week, it’ll probably be new data or deals, but if it’s next week, it could be a buyout, I think.

0 · Reply

aga5757st Mar. 11 at 3:02 PM

0 · Reply

B_B_ Mar. 11 at 2:54 PM

$WVE

0 · Reply

B_B_ Mar. 11 at 2:28 PM

$WVE I can see it in the stars. It’s only a matter of days, not weeks, before Paul drops the news.

1 · Reply

B_B_ Mar. 11 at 1:54 PM

0 · Reply

B_B_ Mar. 11 at 1:47 PM

$WVE Short interest declined by almost 1.6 million shares. https://www.nasdaq.com/market-activity/stocks/wve/short-interest

0 · Reply

B_B_ Mar. 10 at 7:23 PM

$WVE FDA reconsidering Capricor’s snubbed DMD cell therapy after 'lifting' rejection By Darren Incorvaia Mar 10, 2026 The FDA has resumed review of Capricor Therapeutics’ previously rejected Duchenne muscular dystrophy cell therapy following the biotech’s submission of more clinical data, as well as the newly announced upcoming departure of Vinay Prasad, M.D. The agency has “lifted” the complete response letter (CRL) that was issued for deramiocel in July 2025, Capricor said in a March 10 release, and an approval decision is now expected by Aug. 22. ... https://www.fiercebiotech.com/biotech/fda-reconsidering-capricors-snubbed-dmd-cell-therapy-after-more-data-submitted

1 · Reply

erevnon Mar. 10 at 6:03 PM

Canaccord Genuity maintains WAVE Life Sciences $WVE at Buy and raises the price target from $43 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

anachartanalyst Mar. 10 at 5:02 PM

$WVE https://anachart.com/wp-content/uploads/ana_temp/1773162105_soc-img.jpg

0 · Reply

B_B_ Mar. 10 at 4:11 PM

$WVE I think the next leg up for the indices will happen within the hour.

0 · Reply

B_B_ Mar. 10 at 4:05 PM

$WVE Wave Life Sciences Stock Jumps on Fresh Analyst Upgrade TipRanks 53 minutes ago Wave Life Sciences shares moved higher after Canaccord met with management and came away more confident about the company’s drug pipeline, particularly obesity candidate WVE-007 and AATD therapy WVE-006. Following the meeting and a model update that reflected this progress, the firm lifted its price target on the stock to $52 while reiterating its Buy rating. Investors took the renewed endorsement as a sign that Wave’s experimental treatments could create significant future value, helping to justify a richer valuation today. The higher target and maintained bullish stance suggest analysts now see more upside ahead if the pipeline continues to deliver positive data. https://www.tipranks.com/news/catalyst/wave-life-sciences-stock-jumps-on-fresh-analyst-upgrade

0 · Reply

B_B_ Mar. 10 at 3:10 PM

$WVE Key US Senator Investigates FDA Over Rare-Disease Drug Denials By Robert Langreth, Gerry Smith, and Rachel Cohrs Zhang March 10, 2026 A key US Republican senator said he’s launched an investigation into the Food and Drug Administration’s recent denials of treatments for rare diseases, adding political pressure on an agency that’s already in turmoil. Wisconsin Sen. Ron Johnson said he’s seeking the FDA’s written denials to drugmakers, known as complete response letters. He plans to write letters to the agency asking why it denied certain drugs. He said he’s also considering having top FDA officials, including Commissioner Marty Makary, testify before the Senate’s Permanent Subcommittee on Investigations that he chairs. https://www.bloomberg.com/news/articles/2026-03-10/key-us-senator-investigates-fda-over-rare-disease-drug-denials

0 · Reply

B_B_ Mar. 10 at 2:58 PM

$WVE The major indices are expected to rally again today.

0 · Reply

B_B_ Mar. 10 at 1:43 PM

$WVE The volume is likely to increase in the coming days and weeks.

0 · Reply

B_B_ Mar. 10 at 12:32 PM

$WVE Wave Life Sciences price target raised to $52 from $43 at Canaccord TheFly Mar 10, 2026 Canaccord analyst Whitney Ijem raised the firm’s price target on Wave Life Sciences (WVE) to $52 from $43 and keeps a Buy rating on the shares. The firm updated its model after meeting with management and getting updates on its pipeline including WVE-007 for obesity and WVE-006 in AATD. https://www.tipranks.com/news/the-fly/wave-life-sciences-price-target-raised-to-52-from-43-at-canaccord-thefly-news?utm_source=webullapp.com&utm_medium=referral

0 · Reply

B_B_ Mar. 10 at 8:12 AM

$WVE Maybe it’s time for Paul to stop teasing and start sharing the data, deals, and M&A with his investors to help the share price break free from its current manipulative suppression.

0 · Reply

B_B_ Mar. 10 at 7:44 AM

$WVE It would be unusual for Paul to join an obesity panel and highlight key limitations of GLP-1s if WVE-007 did not show strong efficacy or failed to overcome those limitations. "At Wave Life Sciences, we’re we are focused on driving fat loss without muscle loss – all with 1-2x yearly dosing. Our approach addresses some of the key limitations of GLP-1s and I’m excited to talk about WVE-007 and what it could mean for the future of obesity care."

0 · Reply

Market Cap	2.59B
Revenue (ttm)	42.73M
Net Income (ttm)	-204.38M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-478.31%
Debt to Equity Ratio	0.00

Volume	1,780,800
Avg Vol	3,339,666
Day's Range	N/A - N/A
Shares Out	188.26M
Stochastic %K	58%
Beta	-1.77
Analysts	Strong Sell
Price Target	$34.53